Drug Trial Radar · NCT06547216
Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
Last checked: Nov 20, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
Jul 25, 2024
Primary completion
Apr 2030
Study completion Jun 2030
Sponsor
- Lead sponsor
- Avidity Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years, up to 72 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2 Open-label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
Conditions
- FSHD
- FSHD1
- FSHD2
- FMD
- FMD2
- Fascioscapulohumeral Muscular Dystrophy
- Fascioscapulohumeral Muscular Dystrophy Type 1
- Fascioscapulohumeral Muscular Dystrophy Type 2
- Dystrophies, Facioscapulohumeral Muscular
- Dystrophy, Facioscapulohumeral Muscular
- Facioscapulohumeral Muscular Dystrophy 1
- Facioscapulohumeral Muscular Dystrophy 2
- Facio-Scapulo-Humeral Dystrophy
- Atrophy, Facioscapulohumeral
- Atrophies, Facioscapulohumeral
- Facioscapulohumeral Atrophy
- Muscular Dystrophies
- Muscular Dystrophy, Facioscapulohumeral
- FSH Muscular Dystrophy
- Landouzy Dejerine Dystrophy
- Landouzy-Dejerine Muscular Dystrophy
- Dystrophies, Landouzy-Dejerine
- Dystrophy, Landouzy-Dejerine
- Landouzy-Dejerine Syndrome
- Muscular Dystrophy, Landouzy Dejerine
- Progressive Muscular Dystrophy
- FSH
Interventions
AOC 1020Drug
AOC 1020 will be administered via intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse eventsTime frame: Through study completion, up to Day 729
Locations
17 sites in 3 countries. Site status is shown where the registry gives one.
University of California Los Angeles
Los Angeles, California
Stanford University
Palo Alto, California
University of California San Diego
San Diego, California
University of Colorado
Denver, Colorado
University of Florida
Gainesville, Florida
Rare Disease Research
Atlanta, Georgia
Kansas University Medical Center
Kansas City, Kansas
University of Rochester Medical Center
Rochester, New York
Duke University
Durham, North Carolina
Ohio State University
Columbus, Ohio
University of Pennsylvania
Philadelphia, Pennsylvania
University of Texas Southwestern
Dallas, Texas
Virginia Commonwealth University
Richmond, Virginia
University of Washington
Seattle, Washington
University of Ottawa
Ottawa, Ontario, Canada
University College London
London, United Kingdom
University of Sheffield
Sheffield, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.